FDA warning letter
Issue date
10 Oct 2019
Issuing office
Division of Pharmaceutical Quality Operations II
Posted date
22 Oct 2019
Subject
CGMP/Positron Emission Tomography (PET) Drugs/Adulterated
Products & Services
Drugs
Sofie Biosciences
Warning letter
Headquarters
United States of America